Alkermes plc (NASDAQ: ALKS) has become one of the more closely followed names in the neuroscience and sleep-medicine space. With U.S. markets closed for the weekend, the latest regular-session close was $49.06 on August 14, 2026. The shares have climbed roughly 75% year to date from a 52-week low of $25.17, but they remain below the 52-week high of $55.67 set in early July.
The $60 stock price target sits just above that prior peak and just below several bullish Wall Street targets. It is therefore a natural, widely discussed milestone: a decisive break above $60 would confirm that the rally has more than just a single catalyst behind it.
Alkermes is a Dublin-based biopharmaceutical company with a commercial portfolio that includes LYBALVI, ARISTADA, ARISTADA INITIO and VIVITROL, used in schizophrenia, bipolar I disorder and alcohol or opioid dependence. The company has expanded into sleep medicine through its acquisition of Avadel and the once-nightly sodium oxybate product LUMRYZ.
The first quarter of 2026 showed commercial resilience: revenue of $392.9 million exceeded expectations of roughly $362.9 million, and the reported loss per share of $0.40 was narrower than the anticipated $0.54. Full-year 2026 revenue is expected to expand meaningfully, supported by both the legacy psychiatry franchise and the newer sleep portfolio.
The central bull case is the orexin pipeline. Alkermes is developing alixorexton, an orexin 2 receptor agonist being studied in narcolepsy and idiopathic hypersomnia. Phase 2 VIBRANCE-2 results in narcolepsy type 2 showed statistically significant improvements in wakefulness and reductions in excessive daytime sleepiness, which helped trigger a wave of analyst target increases in June and July.
Additional catalysts remain on the calendar. Investors are watching Phase 2 VIBRANCE-3 data in idiopathic hypersomnia and early data for ALKS 7290 in ADHD, both expected in the fourth quarter of 2026. Meanwhile, the Phase 3 REVITALYZ study of LUMRYZ in idiopathic hypersomnia met its primary endpoint, strengthening the commercial rationale for the Avadel acquisition.
Valuation is the most frequently cited obstacle. After a gain of roughly 55% over a three-month stretch into July, some firms argue that much of the orexin opportunity is already reflected in the share price. BofA Securities carries a Sell rating with a $38 target, while H.C. Wainwright remains Neutral with a $43 target. JPMorgan has a Neutral rating and a $61 target, cautioning that competitive and execution risks remain.
Competition is intensifying. Takeda's orexin candidate oveporexton is advancing in narcolepsy type 1, and Eli Lilly's announced acquisition of orexin-focused Centessa signals deeper competition. Generic erosion in the sodium oxybate market also creates a commercial hurdle for LUMRYZ. Recent insider selling has added a cautious signal, though it remains modest relative to overall institutional ownership.
The long-term trend for ALKS remains upward, with the stock building higher lows since late 2025. The first major resistance level is the 52-week high of $55.67; a convincing breakout above that area would open a path toward the round-number $60 zone.
On the downside, support sits in the upper $40s, roughly in line with the rising 50-day moving average, with a deeper demand zone near the mid-$40s. The 200-day moving average, near $38, marks the longer-term trend line that has contained pullbacks during this rally.
Wall Street remains generally constructive, with a consensus Buy or Moderate Buy rating and an average analyst price target near $56. The range is unusually wide: from a low of $38 to a high of $72. Recent targets cluster around the $60 threshold, including $61 at JPMorgan, $62 at Needham, $63 at Stifel, and $65 at Mizuho, Jefferies and Wells Fargo. That places $60 between the consensus average and the more bullish end of the Street's forecast range, making it a credible but not guaranteed objective.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover new opportunities, monitor existing positions, and identify shifting market trends more efficiently. The tool is designed to complement, rather than replace, an investor's own research and risk management. For those following Alkermes and other healthcare names, it offers a structured way to track evolving technical and market signals.
A move to $60 is realistic but not assured. The strongest support comes from a productive clinical pipeline, the Avadel/LUMRYZ expansion, and several analyst targets at or above that level. The principal risks are valuation, competitive pressure in orexin-based sleep medicine, and the normal uncertainty of late-stage drug development. Before $60 can become sustainable, ALKS would likely need to clear the $55.67 resistance level, deliver positive fourth-quarter pipeline data, and avoid deterioration in the broader biotech tape. Investors should monitor clinical readouts, LUMRYZ commercialization, competitor announcements, and whether the stock can hold the upper $40s on any pullback.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that ALKS and VTRS have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ALKS and VTRS's prices will move in lockstep.
| Ticker / NAME | Correlation To ALKS | 1D Price Change % | ||
|---|---|---|---|---|
| ALKS | 100% | -0.79% | ||
| VTRS - ALKS | 32% Poorly correlated | +1.18% | ||
| NBIX - ALKS | 31% Poorly correlated | +1.26% | ||
| AMRX - ALKS | 31% Poorly correlated | +5.10% | ||
| ACET - ALKS | 30% Poorly correlated | +1.45% | ||
| AMLX - ALKS | 26% Poorly correlated | -3.78% | ||
More | ||||
| Ticker / NAME | Correlation To ALKS | 1D Price Change % |
|---|---|---|
| ALKS | 100% | -0.79% |
| Pharmaceuticals: Generic industry (84 stocks) | 7% Poorly correlated | +1.37% |